Cantel Medical Corp

Cantel Medical — Investor Presentation (January 2015)

21 slides from Cantel Medical's investor presentation, Jan 15, 2015

  1. Slide 1: Investor Presentation, January 15, 2015

    FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filings and reports with the Securities and Exchange Commission. Such statements are onl

  2. Slide 2: Cantel Medical Overview

    Cantel Medical Overview The only pure-play in the growing ~$50B Global Infection Prevention & Control Market (“IP&C”) with existing businesses in addressable markets of approximately $6B Government and industry focus on IP&C is a growth driver and largely shields our markets from downward/weak econo

  3. Slide 3: Our Mission Statement

    Our Mission Statement Our Purpose Cantel Medical is dedicated to delivering innovative infection prevention and control (IP&C) products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. Our Business Priorities New Products: Continually

  4. Slide 4: Cantel Medical Facilities

    Cantel Medical Facilities 40 locations in the North America Netherlands Singapore China United Kingdom 1,700 Dedicated Global Employees Italy 4

  5. Slide 5: Category Leadership and Strong Performance

    Endoscopy Leader in automated endoscope reprocessing systems and procedural disposable products Water Purification & Filtration: Leading share in water purification systems to dialysis facilities as well as a suite of sterilants and filtration products Healthcare Disposables: Leading branded portfol

  6. Slide 6: Three Major Synergistic Segments

    Three Major Synergistic Segments Infection Prevention & Control Focus Endoscopy Endoscopy Reprocessing & Procedure Room Products Water Purification & Filtration Medical & Life Science Water Purification & Filters Healthcare Disposables Dental, Hospital, Sterility Assurance Chemistries, Manufacturing

  7. Slide 7: Well-Balanced Portfolio: Three Major Segments

    Well-Balanced Portfolio: Three Major Segments Last 12 Months Ended October 31, 2014 Net Sales $507.3M Operating Income $88.5M1 “All Other” includes Specialty Packaging Products. 1 Before allocation of corporate expenses of ~$16.9M. 2 Earnings Before Interest, Taxes, Depreciation, Amortization, Stock

  8. Slide 8: Long-term Track Record of Strong Growth & Margin Expansion

    *FY’11 Net Debt includes $98M in debt assumed on the first day of fiscal year 2012 upon closing of the Byrne Medical acquisition. Long-term Track Record of Strong Growth & Margin Expansion CAGR ’03 – ’14 16% 21% 8 Strong cash flow generation funds acquisition program with modest leverage

  9. Slide 9: Sustainable Growth Strategy Driven by Four Key Principles

    New Products Sustainable Growth Strategy Driven by Four Key Principles CONTINOUS IMPROVEMENT Market Expansion Strategic Acquisitions 9

  10. Slide 10: Market Expansion: Significant Global Investment in Sales & Marketing

    Market Expansion: Significant Global Investment in Sales & Marketing OR, central sterile, physicians offices, GI–Adenoma detection, etc Endoscopy expansion complete Water and HC disposable teams expanding Accelerating investments Go-direct in UK, Germany, Italy and China Total spending in S&M has mo

  11. Slide 11: New Products: Accelerated Investments in R&D Pipeline

    New Products: Accelerated Investments in R&D Pipeline Product development has grown by more than 2.5x over the last five years Endoscopy Portfolio Chemistry Portfolio Water Purification & Filtration Portfolio Healthcare Disposables Portfolio Broadest range of endoscope reprocessors (AERs) Now launch

  12. Slide 12: Strategic Acquisitions: Investing in all Core Segments & International Capabilities

    Strategic Acquisitions: Investing in all Core Segments & International Capabilities Proven ability to successfully integrate, leverage & grow acquired businesses Endoscopy Water Purification & Filtration Healthcare Disposables Byrne Medical, PuriCore (UK), IMS (Italy), JetPrep New products, new mark

  13. Slide 13: Long-term Growth Drivers: Endoscopy

    Long-term Growth Drivers: Endoscopy Large and growing global addressable market totaling >$4 billion Colorectal cancer is a leading global cause of death, driving worldwide screening and treatment efforts Improved adenoma detection rates will accelerate colonoscopy procedures Single-shot AERs drive

  14. Slide 14: Long-term Growth Drivers: Water Purification & Filtration

    Long-term Growth Drivers: Water Purification & Filtration End Stage Renal Disease patient demographics drive de novo clinic build in the US Market adoption of heat-based water disinfection technology platform Improved IP&C standards for dialysis patients, labor savings to facility operators Upgrade

  15. Slide 15: Long-term Growth Drivers: Healthcare Disposables

    Long-term Growth Drivers: Healthcare Disposables Leading branded player in the US dental market Sterility assurance category adds high growth, higher margin platform Hospital channel presence to drive sales of entire healthcare disposables product portfolio Innovative high margin face masks / pandem

  16. Slide 16: Experienced Executive Team

    Experienced Executive Team Andrew A. Krakauer Chief Executive Officer Jorgen B. Hansen President & Chief Operating Officer Eric W. Nodiff Exec. Vice President General Counsel Craig A. Sheldon Exec. Vice President Chief Financial Officer & Treasurer Seth M. Yellin Sr. Vice President Corporate Develop

  17. Slide 17: Historical P&L Reveals Success of Growth Programs

    Historical P&L Reveals Success of Growth Programs 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Retroactively applies the 3:2 stock splits effective February 2012 and July 2013. 3 Compound Annual Growth Rate. 4 Last twelve months ended October 31, 2

  18. Slide 18: Strong Balance Sheet & Cash Flow Generation

    Strong Balance Sheet & Cash Flow Generation 1 For last twelve months ended October 31, 2014. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Retroactively reflects 3:2 stock splits effective February, 2012 and July, 2013. 18 1 ($ and shares in million

  19. Slide 19: Strategic Objective: Double Sales & EPS from FY13 to FY18

    Strategic Objective: Double Sales & EPS from FY13 to FY18 Successfully completed year one of plan Continued investments in high growth, high margin product lines Focus on channel expansion including international and hospital markets Execute proven acquisition program to accelerate global growth Acc

  20. Slide 20: Cantel Medical - Summary

    Cantel Medical - Summary $507M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high future growth prospects 73% recurring revenue and $97.5M in LTM EBITDAS1 25 successful acquisitions since 2000 Investments in new product development and increased

  21. Slide 21: Thank You!

    % CANTEL MEDICAL THANK YOU!

Cantel Medical — Investor Presentation (January 2015) on 6ix